Header Logo

Connection

Alan Landay to CD8-Positive T-Lymphocytes

This is a "connection" page, showing publications Alan Landay has written about CD8-Positive T-Lymphocytes.
Connection Strength

5.310
  1. Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction. AIDS. 2013 Jun 19; 27(10):1563-71.
    View in: PubMed
    Score: 0.418
  2. Regulatory B cell frequency correlates with markers of HIV disease progression and attenuates anti-HIV CD8? T cell function in vitro. J Leukoc Biol. 2013 May; 93(5):811-8.
    View in: PubMed
    Score: 0.409
  3. CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis. 2008 May 15; 197(10):1402-7.
    View in: PubMed
    Score: 0.293
  4. Immunophenotypic alterations in acute and early HIV infection. Clin Immunol. 2007 Dec; 125(3):299-308.
    View in: PubMed
    Score: 0.281
  5. Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis. 2004 May 15; 189(10):1811-20.
    View in: PubMed
    Score: 0.222
  6. Loss of CD96 Expression as a Marker of HIV-Specific CD8+ T-Cell Differentiation and Dysfunction. Front Immunol. 2021; 12:673061.
    View in: PubMed
    Score: 0.181
  7. CD8+ lymphocytes in pregnancy and HIV infection: characterization of CD8+ subpopulations and CD8+ noncytotoxic antiviral activity. AIDS Res Hum Retroviruses. 1999 May 01; 15(7):665-70.
    View in: PubMed
    Score: 0.157
  8. Higher Body Mass Index Is Associated With Greater Proportions of Effector CD8+ T Cells Expressing CD57 in Women Living With HIV. J Acquir Immune Defic Syndr. 2017 08 15; 75(5):e132-e141.
    View in: PubMed
    Score: 0.139
  9. Systemic Immune Activation and HIV Shedding in the Female Genital Tract. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):155-62.
    View in: PubMed
    Score: 0.125
  10. Interlaboratory variability of CD8 subset measurements by flow cytometry and its applications to multicenter clinical trials. NAID/NICHD Women and Infants Transmission Study Group. Clin Diagn Lab Immunol. 1995 Jul; 2(4):462-8.
    View in: PubMed
    Score: 0.120
  11. Gut dendritic cell activation links an altered colonic microbiome to mucosal and systemic T-cell activation in untreated HIV-1 infection. Mucosal Immunol. 2016 Jan; 9(1):24-37.
    View in: PubMed
    Score: 0.119
  12. Evidence of a selective depletion of a CD16+ CD56+ CD8+ natural killer cell subset during HIV infection. Cytometry. 1995 Mar 15; 22(1):10-5.
    View in: PubMed
    Score: 0.118
  13. Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women. J Acquir Immune Defic Syndr. 2014 Nov 01; 67(3):295-303.
    View in: PubMed
    Score: 0.115
  14. Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. J Infect Dis. 2015 Mar 01; 211(5):780-90.
    View in: PubMed
    Score: 0.114
  15. Regulatory B cells inhibit cytotoxic T lymphocyte (CTL) activity and elimination of infected CD4 T cells after in vitro reactivation of HIV latent reservoirs. PLoS One. 2014; 9(4):e92934.
    View in: PubMed
    Score: 0.111
  16. Characterization of CD4? T-cell immune activation and interleukin 10 levels among HIV, hepatitis C virus, and HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr. 2013 Nov 01; 64(3):232-40.
    View in: PubMed
    Score: 0.107
  17. Association of HIV clinical disease progression with profiles of early immune activation: results from a cluster analysis approach. AIDS. 2013 Jun 01; 27(9):1473-81.
    View in: PubMed
    Score: 0.104
  18. Age-associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women. PLoS One. 2013; 8(1):e55279.
    View in: PubMed
    Score: 0.102
  19. GB virus C infection is associated with altered lymphocyte subset distribution and reduced T cell activation and proliferation in HIV-infected individuals. PLoS One. 2012; 7(11):e50563.
    View in: PubMed
    Score: 0.100
  20. CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies. J Infect Dis. 2012 Jun; 205(11):1730-8.
    View in: PubMed
    Score: 0.096
  21. Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PLoS One. 2012; 7(1):e30306.
    View in: PubMed
    Score: 0.095
  22. HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. AIDS. 2011 Jan 14; 25(2):159-64.
    View in: PubMed
    Score: 0.088
  23. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis. 2010 Jun 15; 201(12):1796-805.
    View in: PubMed
    Score: 0.085
  24. Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis. 2010 Mar 15; 201(6):823-34.
    View in: PubMed
    Score: 0.083
  25. Association of cells with natural killer (NK) and NKT immunophenotype with incident cancers in HIV-infected women. AIDS Res Hum Retroviruses. 2008 Feb; 24(2):163-8.
    View in: PubMed
    Score: 0.072
  26. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis. 2006 May 01; 193(9):1202-10.
    View in: PubMed
    Score: 0.063
  27. Association of selected phenotypic markers of lymphocyte activation and differentiation with perinatal human immunodeficiency virus transmission and infant infection. Clin Diagn Lab Immunol. 2005 May; 12(5):622-31.
    View in: PubMed
    Score: 0.059
  28. Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy. AIDS. 2004 Sep 24; 18(14):1953-6.
    View in: PubMed
    Score: 0.057
  29. Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients. HIV Med. 2004 Jan; 5(1):55-65.
    View in: PubMed
    Score: 0.054
  30. Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugs. J Infect Dis. 2003 Jul 15; 188(2):209-18.
    View in: PubMed
    Score: 0.052
  31. CD8+ T cells that express CD4 on their surface (CD4dimCD8bright T cells) recognize an antigen-specific target, are detected in vivo, and can be productively infected by T-tropic HIV. Blood. 2003 Sep 15; 102(6):2156-64.
    View in: PubMed
    Score: 0.052
  32. Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. J Infect Dis. 2003 Jun 15; 187(12):1924-33.
    View in: PubMed
    Score: 0.052
  33. Monocyte subsets, T cell activation profiles, and stroke in men and women: The Multi-Ethnic Study of Atherosclerosis and Cardiovascular Health Study. Atherosclerosis. 2022 06; 351:18-25.
    View in: PubMed
    Score: 0.048
  34. Circulating CD4+ TEMRA and CD4+ CD28- T cells and incident diabetes among persons with and without HIV. AIDS. 2022 03 15; 36(4):501-511.
    View in: PubMed
    Score: 0.048
  35. T-Cell Immune Dysregulation and Mortality in Women With Human Immunodeficiency Virus. J Infect Dis. 2022 02 15; 225(4):675-685.
    View in: PubMed
    Score: 0.048
  36. Upregulation of CD4 on CD8+ T cells: CD4dimCD8bright T cells constitute an activated phenotype of CD8+ T cells. Immunology. 2001 Jul; 103(3):270-80.
    View in: PubMed
    Score: 0.046
  37. Association of Monocyte Migration Marker CD11b With Pulmonary Function in People Living With HIV. J Acquir Immune Defic Syndr. 2021 03 01; 86(3):344-352.
    View in: PubMed
    Score: 0.045
  38. Food Insecurity and T-cell Dysregulation in Women Living With Human Immunodeficiency Virus on Antiretroviral Therapy. Clin Infect Dis. 2021 03 01; 72(5):e112-e119.
    View in: PubMed
    Score: 0.045
  39. Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy. J Infect Dis. 2020 11 09; 222(11):1837-1842.
    View in: PubMed
    Score: 0.044
  40. Evaluation of thymopoiesis using T cell receptor excision circles (TRECs): differential correlation between adult and pediatric TRECs and na?ve phenotypes. Clin Immunol. 2000 Nov; 97(2):95-101.
    View in: PubMed
    Score: 0.044
  41. T Lymphocyte Subsets Associated With Prevalent Diabetes in Veterans With and Without Human Immunodeficiency Virus. J Infect Dis. 2020 06 29; 222(2):252-262.
    View in: PubMed
    Score: 0.042
  42. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS. 2000 May 05; 14(7):761-70.
    View in: PubMed
    Score: 0.042
  43. Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers. Clin Infect Dis. 2020 04 10; 70(8):1636-1642.
    View in: PubMed
    Score: 0.042
  44. Perforin is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection. AIDS. 1999 Jul 30; 13(11):1295-303.
    View in: PubMed
    Score: 0.040
  45. Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4+ and CD8+ T cells. Clin Immunol. 1999 Jul; 92(1):14-24.
    View in: PubMed
    Score: 0.040
  46. Costimulation of naive CD8(+) lymphocytes induces CD4 expression and allows human immunodeficiency virus type 1 infection. J Virol. 1998 Nov; 72(11):9054-60.
    View in: PubMed
    Score: 0.038
  47. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS. 1998 Jul 30; 12(11):F123-9.
    View in: PubMed
    Score: 0.037
  48. Changes in total, CD4+, and CD8+ lymphocytes during pregnancy and 1 year postpartum in human immunodeficiency virus-infected women. The Women and Infants Transmission Study. Obstet Gynecol. 1997 Jun; 89(6):967-74.
    View in: PubMed
    Score: 0.034
  49. Immunological effects of antiretroviral and immune therapies for HIV. AIDS. 1997; 11 Suppl A:S149-55.
    View in: PubMed
    Score: 0.033
  50. Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects: A Women's interagency HIV study. Medicine (Baltimore). 2016 Aug; 95(33):e4483.
    View in: PubMed
    Score: 0.032
  51. In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: effects of interleukin (IL)-12 and anti-IL-10. J Infect Dis. 1996 May; 173(5):1085-91.
    View in: PubMed
    Score: 0.032
  52. The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. AIDS Res Hum Retroviruses. 2016 07; 32(7):636-47.
    View in: PubMed
    Score: 0.032
  53. Effect of zidovudine therapy on CD8+ T cell anti-HIV activity. Clin Immunol Immunopathol. 1994 Oct; 73(1):80-7.
    View in: PubMed
    Score: 0.029
  54. Increased glucose metabolic activity is associated with CD4+ T-cell activation and depletion during chronic HIV infection. AIDS. 2014 Jan 28; 28(3):297-309.
    View in: PubMed
    Score: 0.027
  55. T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis. 2011 Jul; 217(1):207-13.
    View in: PubMed
    Score: 0.022
  56. Intracellular Casp8p41 content is inversely associated with CD4 T cell count. J Infect Dis. 2010 Aug 15; 202(3):386-91.
    View in: PubMed
    Score: 0.021
  57. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood. 2009 Jun 18; 113(25):6304-14.
    View in: PubMed
    Score: 0.020
  58. Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology. 2007 Sep; 122(1):1-14.
    View in: PubMed
    Score: 0.017
  59. A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther. 2007; 12(4):531-41.
    View in: PubMed
    Score: 0.017
  60. VACUTAINER CPT and Ficoll density gradient separation perform equivalently in maintaining the quality and function of PBMC from HIV seropositive blood samples. BMC Immunol. 2006 May 25; 7:11.
    View in: PubMed
    Score: 0.016
  61. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis. 2006 Jul 01; 194(1):29-37.
    View in: PubMed
    Score: 0.016
  62. Proliferation responses to HIVp24 during antiretroviral therapy do not reflect improved immune phenotype or function. AIDS. 2004 Mar 05; 18(4):605-13.
    View in: PubMed
    Score: 0.014
  63. Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection. J Infect Dis. 2003 Dec 15; 188(12):1804-14.
    View in: PubMed
    Score: 0.013
  64. Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003 Aug 15; 37(4):551-8.
    View in: PubMed
    Score: 0.013
  65. Immune reconstitution after successful treatment with protease inhibitor-based and protease inhibitor-sparing antiretroviral regimens. J Acquir Immune Defic Syndr. 2002 Apr 15; 29(5):544-5.
    View in: PubMed
    Score: 0.012
  66. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS. 2000 Dec 01; 14(17):2635-42.
    View in: PubMed
    Score: 0.011
  67. Maternal immunologic and virologic risk factors for infant human immunodeficiency virus type 1 infection: findings from the Women and Infants Transmission Study. J Infect Dis. 1997 Mar; 175(3):567-75.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.